Mortality in systemic sclerosis

Clinical and Experimental Rheumatology

Volumn 26, Issue 5 SUPPL. 51, 2008, Pages

  Karassa, Fotini B ^a   Ioannidis, John P A ^a,b,c  

^a UNIVERSITY OF IOANNINA   (Greece)

^b INSTITUTE OF COMPUTER SCIENCE   (Greece)

^c TUFTS MEDICAL CENTER   (United States)

Author keywords

Mortality; Predictive factors; Systemic sclerosis

Indexed keywords

ANTINUCLEAR ANTIBODY; AUTOANTIBODY; SCL 70 ANTIBODY;

AGE DISTRIBUTION; ANTIBODY DETECTION; ATTITUDE TO HEALTH; CAUSE OF DEATH; CLINICAL FEATURE; CLINICAL TRIAL; DEMOGRAPHY; DISEASE SEVERITY; ERYTHROCYTE SEDIMENTATION RATE; GASTROINTESTINAL DISEASE; HEART DISEASE; HIGH RISK PATIENT; HUMAN; KIDNEY DISEASE; LABORATORY TEST; LUNG DISEASE; MORTALITY; PATHOGENESIS; PATIENT ATTITUDE; PRIORITY JOURNAL; PROGNOSIS; RACE DIFFERENCE; REVIEW; RISK FACTOR; SCLERODERMA; SEX DIFFERENCE; SURVIVAL RATE; SYSTEMIC SCLEROSIS;

AGE FACTORS; BIOLOGICAL MARKERS; CAUSE OF DEATH; EPIDEMIOLOGIC RESEARCH DESIGN; FEMALE; HUMANS; MALE; ODDS RATIO; SCLERODERMA, DIFFUSE; SCLERODERMA, LIMITED; SEX FACTORS;

EID: 55349101640     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (66)

1. MARICQ HR, WEINRICH MC, KEIL JE et al.: Prevalence of scleroderma spectrum disorders in the general population of South Carolina. Arthritis Rheum 1989; 32: 998-1006.
2. MAYES MD, LACEY JV JR, BEEBE-DIMMER J et al.: Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum 2003; 49: 2246-55.
3. VARGA J, ABRAHAM D: Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 2007; 117: 557-67.
4. JIMENEZ SA, DERK CT: Following the molecular pathways toward an understanding of the pathogenesis of systemic sclerosis. Ann Intern Med 2004; 140: 37-50.
5. CHARLES C, CLEMENTS P, FURST DE: Systemic sclerosis: hypothesis-driven treatment strategies. Lancet 2006; 367: 1683-91.
6. LEROY EC, BLACK C, FLEISCHMAJER R et al.: Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15: 202-5.
7. WOLLHEIM FA: Classification of systemic sclerosis. Visions and reality. Rheumatology (Oxford). 2005; 44: 1212-6.
8. LEROY EC, MEDSGER TA JR: Criteria for the classification of early systemic sclerosis. J Rheumatol 2001; 28: 1573-6.
9. FERRI C, VALENTINI G, COZZI F et al.: Systemic Sclerosis Study Group of the Italian Society of Rheumatology (SIR-GSSSc). Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine (Baltimore) 2002; 81: 139-53.
10. SCUSSEL-LONZETTI L, JOYAL F, RAYNAULD JP et al.: Predicting mortality in systemic sclerosis: analysis of a cohort of 309 French Canadian patients with emphasis on features at diagnosis as predictive factors for survival. Medicine (Baltimore) 2002; 81: 154-67.
11. FARMER RG, GIFFORD RW JR, HINES EA JR: Prognostic significance of Raynaud's phenomenon and other clinical characteristics of systemic scleroderma. A study of 271 cases. Circulation 1960; 21: 1088-95.
12. TUFFANELLI DL, WINKELMANN RK: Systemic scleroderma, A clinical study of 727 cases. Arch Dermatol 1961; 84: 359-71.
13. MEDSGER TA Jr, MASI AT, RODNAN GP, BENEDEK TG, ROBINSON H: Survival with systemic sclerosis (scleroderma). A life-table analysis of clinical and demographic factors in 309 patients. Ann Intern Med 1971; 75: 369-76.
14. WYNN J, FINEBERG N, MATZER L et al.: Prediction of survival in progressive systemic sclerosis by multivariate analysis of clinical features. Am Heart J 1985; 110: 123-7.
15. SILMAN AJ: Scleroderma and survival. Ann Rheum Dis 1991; 50: 267-9.
16. AMERICAN RHEUMATISM ASSOCIATION: Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980; 23: 581-90.
17. WIGLEY FM: When is scleroderma really scleroderma? J Rheumatol 2001; 28: 1471-3.
18. POORMOGHIM H, LUCAS M, FERTIG N, MEDSGER TA JR: Systemic sclerosis sine scleroderma: demographic, clinical, and serologic features and survival in forty-eight patients. Arthritis Rheum 2000; 43: 444-51.
19. UNITED NATIONS, STATISTICAL OFFICE: Monthly Bulletin of Statistics. New York, New York: United Nations, Statistical Office; 1980-2000.
20. IOANNIDIS JP, VLACHOYIANNOPOULOS PG, HAIDICH AB et al.: Mortality in systemic sclerosis: an international meta-analysis of individual patient data. Am J Med 2005; 118: 2-10.
21. ABU-SHAKRA M, LEE P: Mortality in systemic sclerosis: a comparison with the general population. J Rheumatol 1995; 22: 2100-2.
22. BRYAN C, HOWARD Y, BRENNAN P, BLACK C, SILMAN A: Survival following the onset of scleroderma: results from a retrospective inception cohort study of the UK patient population. Br J Rheumatol 1996; 35: 1122-6.
23. JACOBSEN S, HALBERG P, ULLMAN S: Mortality and causes of death of 344 Danish patients with systemic sclerosis (scleroderma). Br J Rheumatol 1998; 37: 750-5.
24. HESSELSTRAND R, SCHEJA A, AKESSON A: Mortality and causes of death in a Swedish series of systemic sclerosis patients. Ann Rheum Dis 1998; 57: 682-6.
25. SIMEON CP, ARMADANS L, FONOLLOSA V et al.: Mortality and prognostic factors in Spanish patients with systemic sclerosis. Rheumatology (Oxford) 2003; 42: 71-5.
26. ROWELL NR: The prognosis of systemic sclerosis. Br J Dermatol 1976; 95: 57-60.
27. MEDSGER TA JR, MASI AT: Survival with scleroderma. II. A life-table analysis of clinical and demographic factors in 358 male U.S. veteran patients. J Chronic Dis 1973; 26: 647-60.
28. CHUNG L, KRISHNAN E, CHAKRAVARTY EF: Hospitalizations and mortality in systemic sclerosis: results from the Nationwide Inpatient Sample. Rheumatology (Oxford) 2007; 46: 1808-13.
29. KRISHNAN E, FURST DE: Systemic sclerosis mortality in the United States: 1979-1998. Eur J Epidemiol 2005; 20: 855-61.
30. ALTMAN RD, MEDSGER TA JR, BLOCH DA, MICHEL BA: Predictors of survival in systemic sclerosis (scleroderma). Arthritis Rheum 1991; 34: 403-13.
31. KABURAKI J, LEE CC, KUWANA M et al.: Initial predictors of survival in patients with systemic sclerosis (scleroderma). Keio J Med 1992; 41: 141-5.
32. NISHIOKA K, KATAYAMA I, KONDO H et al.: Epidemiological analysis of prognosis of 496 Japanese patients with progressive systemic sclerosis (SSc). Scleroderma Research Committee Japan. J Dermatol 1996; 23: 677-82.
33. RUANGJUTIPOPAN S, KASITANON N, LOUTHRENOO W, SUKITAWUT W, WICHAINUN R: Causes of death and poor survival prognostic factors in Thai patients with systemic sclerosis. J Med Assoc Thai 2002; 85: 1204-9.
34. BENNETT R, BLUESTONE R, HOLT PJ, BYWATERS EG: Survival in scleroderma. Ann Rheum Dis 1971; 30: 591-8.
35. DERK CT, ARTLETT CM, JIMENEZ SA: Morbidity and mortality of patients diagnosed with systemic sclerosis after the age of 75: a nested case-control study. Clin Rheumatol 2006; 25: 831-4.
36. LEE P, LANGEVITZ P, ALDERDICE CA et al.: Mortality in systemic sclerosis (scleroderma). Q J Med 1992; 82: 139-48.
37. CZIRJAK L, KUMANOVICS G, VARJU C, NAGY Z, PAKOZDI A, SZEKANECZ Z, SZUCS G: Survival and causes of death in 366 Hungarian patients with systemic sclerosis. Ann Rheum Dis 2008; 67: 59-63.
38. MENDOZA F, DERK CT: Systemic sclerosis mortality in the United States: 1999-2002 implications for patient care. J Clin Rheumatol 2007; 13: 187-92.
39. NIETERT PJ, SILVER RM, MITCHELL HC, SHAFTMAN SR, TILLEY BC: Demographic and clinical factors associated with in-hospital death among patients with systemic sclerosis. J Rheumatol 2005; 32: 1888-92.
40. JACOBSEN S, ULLMAN S, SHEN GQ, WIIK A, HALBERG P: Influence of clinical features, serum antinuclear antibodies, and lung function on survival of patients with systemic sclerosis. J Rheumatol 2001; 28: 2454-9.
41. SHAND L, LUNT M, NIHTYANOVA S et al.: Relationship between change in skin score and disease outcome in diffuse cutaneous systemic sclerosis: application of a latent linear trajectory model. Arthritis Rheum 2007; 56: 2422-31.
42. STEEN VD, MEDSGER TA JR: Improvement in skin thickening in systemic sclerosis associated with improved survival. Arthritis Rheum 2001; 44: 2828-35.
43. CLEMENTS PJ, HURWITZ EL, WONG WK et al.: Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: high-dose versus low-dose penicillamine trial. Arthritis Rheum 2000; 43: 2445-54.
44. BRYAN C, KNIGHT C, BLACK CM, SILMAN AJ: Prediction of five-year survival following presentation with scleroderma: development of a simple model using three disease factors at first visit. Arthritis Rheum 1999; 42: 2660-5.
45. GOH NS, VEERARAGHAVAN S, DESAI SR et al.: Bronchoalveolar lavage cellular profiles in patients with systemic sclerosis-associated interstitial lung disease are not predictive of disease progression. Arthritis Rheum 2007; 56: 2005-12.
46. TRAD S, AMOURA Z, BEIGELMAN C et al.: Pulmonary arterial hypertension is a major mortality factor in diffuse systemic sclerosis, independent of interstitial lung disease. Arthritis Rheum 2006; 54: 184-91.
47. MUKERJEE D, ST GEORGE D, COLEIRO B et al.: Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 2003; 62: 1088-93.
48. MACGREGOR AJ, CANAVAN R, KNIGHT C et al.: Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival. Rheumatology (Oxford) 2001; 40: 453-9.
49. STEEN VD, MEDSGER TA JR: Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 2000; 43: 2437-44.
50. BULPITT KJ, CLEMENTS PJ, LACHENBRUCH PA et al.: Early undifferentiated connective tissue disease: III. Outcome and prognostic indicators in early scleroderma (systemic sclerosis). Ann Intern Med 1993; 118: 602-9.
51. MEDSGER TA JR, SILMAN AJ, STEEN VD et al.: A disease severity scale for systemic sclerosis: development and testing. J Rheumatol 1999; 26: 2159-67.
52. GEIRSSON AJ, WOLLHEIM FA, AKESSON A: Disease severity of 100 patients with systemic sclerosis over a period of 14 years: using a modified Medsger scale. Ann Rheum Dis 2001; 60: 1117-22.
53. BARNETT AJ, MILLER MH, LITTLEJOHN GO: A survival study of patients with scleroderma diagnosed over 30 years (1953-1983): the value of a simple cutaneous classification in the early stages of the disease. J Rheumatol 1988; 15: 276-83.
54. STEEN VD, POWELL DL, MEDSGER TA JR: Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum 1988; 31: 196-203.
55. KUWANA M, KABURAKI J, OKANO Y, TOJO T, HOMMA M: Clinical and prognostic associations based on serum antinuclear antibodies in Japanese patients with systemic sclerosis. Arthritis Rheum 1994; 37: 75-83.
56. JACOBSEN S, HALBERG P, ULLMAN S et al.: Clinical features and serum antinuclear antibodies in 230 Danish patients with systemic sclerosis. Br J Rheumatol 1999; 37: 39-45.
57. PERERA A, FERTIG N, LUCAS M et al.: Clinical subsets, skin thickness progression rate, and serum antibody levels in systemic sclerosis patients with anti-topoisomerase I antibody. Arthritis Rheum 2007; 56: 2740-6.
58. STEEN VD, MEDSGER TA: Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 2007; 66: 940-4.
59. PAPANIKOLAOU PN, CHRISTIDI GD, IOANNIDIS JPA: Patient outcomes with teaching versus nonteaching healthcare: a systematic review. PLoS Med 2006; 3: e341.
60. HALM EA, LEE C, CHASSIN MR: Is volume related to outcome in health care? A systematic review and methodologic critique of the literature. Ann Intern Med 2002; 137: 511-20.
61. KYZAS PA, LOIZOU KT, IOANNIDIS JP: Selective reporting biases in cancer prognostic factor studies. J Natl Cancer Inst 2005; 97: 1023-5.
62. KYZAS PA, DENAXA-KYZA D, IOANNIDIS JP: Almost all articles on cancer prognostic markers report statistically significant results. Eur J Cancer 2007; 43: 2559-79.
63. CHAN AW, ALTMAN DG: Identifying outcome reporting bias in randomised trials on PubMed: review of publications and survey of authors. BMJ 2005; 330: 753.
64. IOANNIDIS JP: Why most published research findings are false. PLoS Med 2005; 2: e124.
65. IOANNIDIS JP: Why most discovered true associations are inflated. Epidemiology 2008 July 14. [Epub ahead of print]
66. KYZAS PA, DENAXA-KYZA D, IOANNIDIS JP: Quality of reporting of cancer prognostic marker studies: association with reported prognostic effect. J Natl Cancer Inst 2007; 99: 236-43.